botulinum toxin type a: clinical use

Prescribing considerations

• Confirm the exact licensed indication and product-specific administration requirements; never convert or substitute units between brands.
• Treatment requires appropriately qualified practitioners with relevant anatomical expertise and guidance equipment where indicated.
• Set a measurable therapeutic goal and assess response, local weakness and functional consequences.
• Review previous toxin exposure, neuromuscular disease, dysphagia or aspiration, respiratory impairment, bleeding risk, anticoagulants and interacting medicines.
• Use authorised products from legitimate supply chains and record the product name and batch number.

Contraindications and cautions

• Hypersensitivity to the active substance or formulation excipients
• Infection, or for Xeomin infection or inflammation, at the proposed injection site
• Generalised disorders of muscle activity such as myasthenia gravis or Lambert–Eaton syndrome
• Amyotrophic lateral sclerosis is specifically contraindicated for Azzalure and Relfydess

Monitoring

• Monitor for excessive local weakness and delayed distant toxin effects, including dysphagia, dysarthria, respiratory symptoms and generalised weakness.
• After periocular treatment, assess eyelid position, eye closure, visual symptoms and corneal exposure risk where clinically indicated.
• For sialorrhoea, monitor swallowing, dry mouth and oral or dental health.
• Review whether the treatment goal was achieved and document adverse effects.

Clinical pharmacology

Botulinum toxin type A blocks acetylcholine release from presynaptic cholinergic nerve terminals through cleavage of SNAP-25, causing reversible chemical denervation and reduced activity in the targeted muscle or gland.

Formulation and product differences

• Xeomin is a powder requiring reconstitution and contains purified neurotoxin without complexing proteins; its excipients include human albumin and sucrose.
• Azzalure is a powder requiring reconstitution and contains a botulinum toxin type A haemagglutinin complex measured in product-specific Speywood units.
• Relfydess is a ready-to-use solution containing botulinum toxin type A with polysorbate 80; polysorbates may cause allergic reactions.
• Potency assays and units are product-specific and not interchangeable.

Injection

Route: Parenteral

Strengths: 50 units, 50 units + 100 units + 200 units, 100 units, 100 units/mL